Long-Acting Lipoglycopeptides in Orthopedic and Cardiovascular Device-Associated Infections: Outcomes According to Source-Control Strategy in a Multicenter Day-Hospital Cohort
Antibiotics · 18.11.2026 · 15 (11) · 1150
DOI: 10.3390/antibiotics15111150 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antibiotics, online erschienen am 18.11.2026. Verfasst von Andrea Marino und 21 weiteren Autor:innen. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Long-acting lipoglycopeptides (LALs) can simplify prolonged anti-Gram-positive therapy, but evidence in infections involving orthopedic or cardiovascular prosthetic material remains limited, particularly in relation to surgical source control.
Methods
We performed a post hoc secondary analysis of a previously published multicenter day-hospital cohort. Adults with orthopedic or cardiovascular prosthetic material and a deep-seated or device-associated infection treated with at least one dose of dalbavancin and/or oritavancin between January 2020 and December 2025 were included; patients with an unrelated acute bacterial skin and skin-structure infection were excluded. Clinical outcomes were examined according to eventual device management (retention versus removal; total versus partial explantation).
Results
Forty-six patients were included; median age was 72.3 years (IQR 60.4–79.1) and median Charlson Comorbidity Index was 4 (IQR 2.2–6.0). Prosthetic joint infection accounted for 25/46 cases (54.3%). Forty-five patients received a dalbavancin-containing regimen and 31/46 (67.4%) received LAL monotherapy. Clinical success at last available follow-up was 87.0% (40/46; exact 95% CI 73.7–95.1). Among the 40 patients with a classified source-control strategy and an infection involving the recorded device, success was 88.9% with retention (16/18) and 86.4% with removal (19/22); the exact conditional odds ratio was 1.26 (95% CI 0.13–16.79; Fisher p = 1.000). After removal, success was 89.5% after total explantation (17/19) and 66.7% after partial removal (2/3). C-reactive protein fell from 3.65 to 0.91 mg/dL (p < 0.001). Adverse drug events were mild and infrequent (2/40).
Conclusions
In this post hoc, uncontrolled device-focused analysis, LAL-based day-hospital management was feasible with favorable observed outcomes. The source-control comparison was imprecise and cannot support superiority of retention or removal; it should be interpreted as descriptive and hypothesis-generating. Follow-up duration was not standardized, so durable cure could not be assessed.
Zitieren
APA
Marino, A., Rullo, E. V., Pipitone, G., Geremia, A. G., Vito, A. D., Albanese, A., Geremia, N., Franzò, A., Bellocchi, B., Pistarà, E., Italia, P., Catania, B., Buzzi, A., Santoro, L., Spampinato, S., Iaria, C., Madeddu, G., Iacobello, C., Manuele, R., …, & Nunnari, G. (2026). Long-Acting Lipoglycopeptides in Orthopedic and Cardiovascular Device-Associated Infections: Outcomes According to Source-Control Strategy in a Multicenter Day-Hospital Cohort. Antibiotics, 15(11), 1150. https://doi.org/10.3390/antibiotics15111150
Vancouver
Marino A, Rullo EV, Pipitone G, Geremia AG, Vito AD, Albanese A, et al. Long-Acting Lipoglycopeptides in Orthopedic and Cardiovascular Device-Associated Infections: Outcomes According to Source-Control Strategy in a Multicenter Day-Hospital Cohort. Antibiotics. 2026;15(11):1150. doi:10.3390/antibiotics15111150
BibTeX
@article{Marino2026,
author = {Marino, Andrea and Rullo, Emmanuele Venanzi and Pipitone, Giuseppe and Geremia, Alessandro Giorgio and Vito, Andrea De and Albanese, Antonio and Geremia, Nicholas and Franzò, Alessandro and Bellocchi, Barbara and Pistarà, Eugenia and Italia, Paolo and Catania, Bianca and Buzzi, Andrea and Santoro, Laura and Spampinato, Serena and Iaria, Chiara and Madeddu, Giordano and Iacobello, Carmelo and Manuele, Rosa and Pulvirenti, Fabrizio and Cacopardo, Bruno and Nunnari, Giuseppe},
title = {Long-Acting Lipoglycopeptides in Orthopedic and Cardiovascular Device-Associated Infections: Outcomes According to Source-Control Strategy in a Multicenter Day-Hospital Cohort},
journal = {Antibiotics},
year = {2026},
volume = {15},
number = {11},
pages = {1150},
doi = {10.3390/antibiotics15111150}
}
EUVIMED